Trial Profile
Multi-center study on prediction of response to cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 15 Nov 2017 New trial record